Duthaler Urs, Sayasone Somphou, Vanobbergen Fiona, Penny Melissa A, Odermatt Peter, Huwyler Jörg, Keiser Jennifer
Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland.
National Institute of Public Health, Ministry of Health, Vientiane, Lao People's Democratic Republic.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5705-15. doi: 10.1128/AAC.00992-16. Print 2016 Oct.
Praziquantel is the only drug available for the treatment of Opisthorchis viverrini infections. Tribendimidine has emerged as a potential treatment alternative; however, its pharmacokinetic (PK) properties have not been sufficiently studied to date. Via two phase IIa dose-finding studies, 68 O. viverrini patients were treated with 25- to 600-mg doses of tribendimidine using 50- and 200-mg tablet formulations. Plasma, blood, and dried blood spots (DBS) were sampled at selected time points. The two main metabolites of tribendimidine, active deacetylated amidantel (dADT) and acetylated dADT (adADT), were analyzed in plasma, blood, and DBS. PK parameters were estimated by noncompartmental analysis. An acceptable agreement among plasma and DBS concentrations was observed, with a mean bias of ≤10%, and 60% dADT and 74% adADT concentrations being within ±20% margins. We found that 200-mg tribendimidine tablets possess immediate floating characteristics, which led to variable time to maximal concentration of drug (Tmax) values (2 to 24 h) between individuals. Dose proportionality was observed for dADT from 25 to 200 mg using 50-mg tablets, but at higher dosages (200 to 600 mg), saturation occurred. The median ratio of the area under the plasma concentration-time curve from 0 to 24 h (AUC0-24) of dADT to the AUC0- 24 of adADT ranged from 0.8 to 26.4, suggesting substantial differences in acetylation rates. Cure rates ranged from 11% (25-mg dose) to 100% (400-mg dose). Cured patients showed significantly higher dADT maximal serum concentrations (Cmax) and AUC0-24 values than uncured patients. Tribendimidine is a promising drug for the treatment of opisthorchiasis. However, the tablet formulation should be optimized to achieve consistent absorption among patients. Further studies are warranted to assess the large differences between individuals in the rate of metabolic turnover of dADT to adADT. (This study has been registered with the ISRCTN Registry under no. ISRCTN96948551.).
吡喹酮是唯一可用于治疗华支睾吸虫感染的药物。三苯双脒已成为一种潜在的替代治疗药物;然而,其药代动力学(PK)特性迄今尚未得到充分研究。通过两项IIa期剂量探索研究,68例华支睾吸虫病患者使用50毫克和200毫克片剂剂型,接受了25至600毫克剂量的三苯双脒治疗。在选定的时间点采集血浆、血液和干血斑(DBS)样本。在血浆、血液和DBS中分析了三苯双脒的两种主要代谢产物,即活性脱乙酰酰胺苯硫醚(dADT)和乙酰化dADT(adADT)。通过非房室分析估算PK参数。观察到血浆和DBS浓度之间具有可接受的一致性,平均偏差≤10%,60%的dADT和74%的adADT浓度在±20%范围内。我们发现200毫克三苯双脒片剂具有速释漂浮特性,这导致个体之间药物达峰时间(Tmax)值(2至24小时)存在差异。使用50毫克片剂时,观察到dADT在25至200毫克剂量范围内呈剂量比例关系,但在较高剂量(200至600毫克)时出现饱和。dADT的0至24小时血浆浓度-时间曲线下面积(AUC0-24)与adADT的AUC0-24的中位数比值在0.8至26.4之间,表明乙酰化率存在显著差异。治愈率范围为11%(25毫克剂量)至100%(400毫克剂量)。治愈患者的dADT最大血清浓度(Cmax)和AUC0-24值显著高于未治愈患者。三苯双脒是一种有前景的治疗华支睾吸虫病的药物。然而,应优化片剂剂型,以实现患者之间一致的吸收。有必要进一步研究评估个体之间dADT向adADT代谢转化速率的巨大差异。(本研究已在ISRCTN注册中心注册,注册号为ISRCTN96948551。)